Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipThromboserin Ltd. is an ‘innovator’ research company and their mission is to focus primarily on preventing arterial thrombosis. TH001 was granted a US Patent in December 2015, giving them IP until 2030.
Thromboserin is a biotechnology company dedicated to advancing the treatment of thrombotic diseases, particularly in the areas of blood clotting and related disorders. The company specialises in developing innovative therapies that aim to improve patient outcomes by addressing the underlying causes of thrombosis. With a strong focus on research and scientific discovery, Thromboserin is committed to pioneering new solutions that provide safer, more effective alternatives to current treatment options. Through its cutting-edge research, the company strives to make a meaningful impact on the global fight against thrombosis and related diseases.
Thromboserin first approached Niche to create the Investigator's Brochure (IB) for their product, TH001. This was particularly challenging as the information provided by the original Sponsor was poor quality and in hard copy only. Niche's renowned expertise in the writing of IBs ensured the quick and effective delivery of this document which was used to inform Thromboserin’s Protocol and subsequently used to build their Clinical Trial Application. Niche also aided Thromboserin’s search for development partners to support the company in their clinical development.